General Information:

Id: 407
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Rattus norvegicus
male
adenoviral construct to overexpress hepatic GPAT1 (Ad-GPAT1)
article
Reference: Nagle CA et al.(2007) Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance J. Biol. Chem. 282 [PMID: 17389595]

Interaction Information:

Comment Hepatic overexpression of GPAT causes hepatic steatosis, hypertriglyceridemia, and muscle TAG accumulation.
Formal Description
Interaction-ID: 1752

gene/protein

GPAM

affects_activity of

disease

Fatty liver disease, nonalcoholic

Comment Hepatic overexpression of GPAT causes hepatic steatosis, hypertriglyceridemia, and muscle TAG accumulation.
Formal Description
Interaction-ID: 1771

gene/protein

GPAM

affects_quantity of

drug/chemical compound

Triacylglycerol

in liver, in muscle
Comment Hepatic overexpression of GPAT1 causes insulin resistance, liver was the predominant site of insulin resistance.
Formal Description
Interaction-ID: 1788

gene/protein

GPAM

affects_activity of

disease

Insulin resistance

Comment Rats overexpressing GPAT1 had 2.5-fold higher hepatic glucose-output than controls during a hyperinsulinemic-euglycemic clamp.
Formal Description
Interaction-ID: 1789

gene/protein

GPAM

affects_quantity of

drug/chemical compound

Glucose

if GPAM is overexpressed in liver
Comment Hepatic diacylglycerol and lysophosphatidate were elevated in Ad-GPAT1 rats, suggesting a role for these lipid metabolites in the development of hepatic insulin resistance, and hepatic protein kinase C-epsilon was activated, providing a potential mechanism for insulin resistance.
Formal Description
Interaction-ID: 1790

gene/protein

GPAM

affects_quantity of

drug/chemical compound

Diacylglycerol

Comment Hepatic diacylglycerol and lysophosphatidate were elevated in Ad-GPAT1 rats, suggesting a role for these lipid metabolites in the development of hepatic insulin resistance, and hepatic protein kinase C-epsilon was activated, providing a potential mechanism for insulin resistance.
Formal Description
Interaction-ID: 1791

gene/protein

GPAM

affects_quantity of

drug/chemical compound

Lysophosphatidic acid

Comment Ad-GPAT1-treated rats had 50% lower hepatic NF-kappa-B activity and no difference in expression of tumor necrosis factor-alpha and interleukin-beta, consistent with hepatic insulin resistance in the absence of increased hepatic inflammation.
Formal Description
Interaction-ID: 1793

gene/protein

GPAM

NOT affects_expression of

gene/protein

TNF

Drugbank entries Show/Hide entries for TNF
Comment Ad-GPAT1-treated rats had 50% lower hepatic NF-kappa-B activity and no difference in expression of tumor necrosis factor-alpha and interleukin-beta, consistent with hepatic insulin resistance in the absence of increased hepatic inflammation.
Formal Description
Interaction-ID: 1796

gene/protein

GPAM

NOT affects_expression of

gene/protein

IL1B

Drugbank entries Show/Hide entries for IL1B
Comment Ad-GPAT1-treated rats had 50% lower hepatic NF-kappa-B activity and no difference in expression of tumor necrosis factor-alpha and interleukin-beta, consistent with hepatic insulin resistance in the absence of increased hepatic inflammation.
Formal Description
Interaction-ID: 1797

gene/protein

GPAM

affects_activity of

complex/PPI

NF-kappaB complex

in liver
Comment Ad-GPAT1-treated rats had 50% lower hepatic NF-kappa-B activity and no difference in expression of tumor necrosis factor-alpha and interleukin-beta, consistent with hepatic insulin resistance in the absence of increased hepatic inflammation.
Formal Description
Interaction-ID: 1798

gene/protein

GPAM

NOT affects_activity of

phenotype

liver inflammation

in liver
Comment In rats overexpressing hepatic GPAT1 the glycogen synthesis and uptake of 2-deoxyglucose were reduced in skeletal muscle, suggesting mild peripheral insulin resistance associated with a higher content of skeletal muscle triacylglycerol.
Formal Description
Interaction-ID: 1799

gene/protein

GPAM

decreases_activity of

process

glycogen biosynthetic process

in skeletal muscle; if GPAM is overexpressed in liver
Comment In rats overexpressing hepatic GPAT1 the glycogen synthesis and uptake of 2-deoxyglucose were reduced in skeletal muscle, suggesting mild peripheral insulin resistance associated with a higher content of skeletal muscle triacylglycerol.
Formal Description
Interaction-ID: 12710

gene/protein

GPAM

increases_quantity of

drug/chemical compound

Triacylglycerol

in skeletal muscle; if GPAM is overexpressed in liver